MJB ADHD · Static reading view · Interactive version
Status: sourced-draft · Content checked 2026-10-07
A practical guide to recognition, motor and non-motor symptoms, treatment choices, medication continuity, genetics and research, with sources and questions to take to a specialist.
Parkinson’s is often described as a dopamine problem. That helps explain an important treatment target, but it is too small a description of the person’s experience. This guide connects recognition, daily function, treatment and continuity of care. Use the depth controls to stop at the detail you need.
Parkinson’s involves damage to dopamine-producing nerve cells in the substantia nigra. The cause is usually not known; age, genetic susceptibility and environmental factors are involved. Dopamine loss is part of the explanation, not a test you can perform on yourself.
F10Movement problems can coexist with pain, fatigue, sleep disturbance, bowel or bladder difficulties, and changes in mood or thinking. Symptoms and their impact vary between people and can fluctuate within a day.
PD-SYMIf you need one useful next step: describe what has changed, when it began, which everyday activities are affected, and what decision you need from the care team. A clear account of function can be more useful than choosing a mechanism first.
Diagnosis is based on the history and a detailed examination. No routine test conclusively establishes Parkinson’s on its own. Suspected Parkinson’s warrants specialist assessment, and selected scans may help answer particular diagnostic questions.
F11Characteristic features include slow movement, rigidity and tremor, often starting on one side. The condition can also affect balance, cognition and mood. A symptom’s presence, severity and evolution matter together.
PD-GENA useful appointment record separates what you experience from what was found on examination. “My leg feels stiff” and “the examiner documented rigidity” are different pieces of information. Ask the clinician to explain the examination findings in plain language.
Parkinsonism describes a movement pattern rather than one single cause. Some medicines, vascular disease and other neurodegenerative conditions can produce parkinsonian features. Identifying the cause requires clinical assessment.
PD-DIFFA label shared between conditions does not make their causes, prognosis or treatments interchangeable. Related reading on this site covers Dystonia: patterned twisting and spasms, Stiffness, spasms and spasticity, Coordination and balance: understanding ataxia, Hereditary spastic paraplegia: what assessment looks for and Dopamine-responsive dystonia: a distinct clinical question. Those routes help organise observations; they do not supply a diagnosis by analogy.
Questions worth taking in:
Pain, fatigue, a feeling of compression or a response to a stimulant cannot by themselves settle that assessment. A treatment response is an observation to document, not permission to choose or escalate a drug independently.
Parkinson’s can involve tremor, stiffness, slowness, freezing, cramps or dystonia, and balance difficulties. Not everyone has the same combination. The functional effect may be more important to the person than how conspicuous a symptom appears.
PD-SYMFor your own notes, choose a few activities you can describe without exhausting yourself: getting out of a chair, turning, dressing, writing, using cutlery or walking through a doorway. Record what is difficult and what helps. If you use video, agree how the clinician can receive it securely.
Non-motor difficulties can include pain, fatigue, constipation, urinary problems, low blood pressure, sleep disruption and changes in communication. Anxiety, depression, hallucinations and thinking or memory changes also merit assessment.
PD-SYMThese concerns belong in the care discussion even when the appointment concentrates on movement. Ask for a plan for the problem that limits life most today, and an owner for each referral or review.
Sleep difficulties can have several forms, including insomnia, daytime sleepiness and acting out dreams during REM sleep. Parkinson’s symptoms and medicines can contribute. Describe the pattern to the care team so it can be assessed rather than treated as one generic sleep problem.
PD-SLEEPSwallowing problems can affect eating, drinking and saliva management. Difficulty swallowing, repeated coughing with meals or changes in intake should be discussed promptly; a speech and language therapist can assess swallowing and support a safer plan.
PD-SWALLOWA sudden new problem needs timely clinical assessment rather than a long reading exercise. Report abrupt deterioration or new confusion to the responsible team; use emergency services for immediate danger.
NICE recommends levodopa when early Parkinson’s motor symptoms affect quality of life. When they do not, choices can include levodopa, a dopamine agonist or an MAO-B inhibitor, discussed with the person.
F9Medicines can improve movement symptoms, but benefits and adverse effects differ. Treatment should be reviewed as needs change. Parkinson’s currently has no cure; symptom relief and slowing the underlying disease are different outcomes.
F12| Option | Main role | Useful review question |
|---|---|---|
| Levodopa with carbidopa or benserazide | Supplies a precursor converted to dopamine; the partner limits breakdown outside the brain | Which activities improve, for how long, and what adverse effects occur? |
| Dopamine agonists | Stimulate dopamine receptors | How will sleepiness, hallucinations and changes in impulse control be checked? |
| MAO-B inhibitors | Reduce dopamine breakdown | What added benefit is expected, and which other medicines need review? |
| COMT inhibitors | Prolong levodopa availability | Is the problem return of symptoms between doses, and how will benefit be recorded? |
| Specialist non-oral treatment | Addresses symptoms insufficiently controlled with tablets | What are the eligibility criteria, delivery demands and follow-up arrangements? |
Treatment overview sources: F12F9. This is a comparison of roles, not a prescribing sequence or dose calculator.
Dopaminergic treatment can cause impulse-control problems, particularly with dopamine agonists. Discuss warning signs and monitoring with the prescriber; involve a trusted person where appropriate, because changes may be difficult to recognise yourself.
F9Parkinson’s drugs have different delivery methods and adverse effects. The charity’s drug resources include wearing-off and involuntary movements, alongside medicine-specific information. Use those topics to prepare a focused review rather than assuming any change means a medicine has simply stopped working.
PD-DRUGSA short diary can help communicate changes in symptoms and treatment response. Record medicine times, what changed and the practical effect; use a manageable format rather than trying to document every minute.
PD-DIARYDeep brain stimulation is an option for selected people whose symptoms are not adequately managed with medication. It involves implanted stimulation and specialist assessment, programming and follow-up. It does not cure Parkinson’s and is not suitable for everyone.
PD-DBSKeep the outcomes separate: easier movement, less off-time, safer swallowing, better sleep and altered disease progression are not the same claim. Ask which outcome a proposed intervention is expected to change.
Most Parkinson’s is not inherited in a simple family pattern. Some genetic differences increase susceptibility; a smaller group can cause inherited forms. Carrying a difference does not always mean the person will develop Parkinson’s.
PD-FAMILYExamples associated with familial Parkinson’s include LRRK2, SNCA, PRKN, PINK1 and PARK7. Some GBA1 variants increase risk. Genetic explanations involve protein handling and cellular energy processes as well as dopamine signalling, with different inheritance patterns between genes.
PD-GENThe reason to examine these systems is to identify testable questions and appropriately targeted evidence. Similar downstream symptoms can arise through different upstream mechanisms; a shared pathway word does not prove that two diagnoses are the same condition.
For the site’s broader causal work: Genetics — many small influences, The dopamine and noradrenaline supply chain and Dopamine-related treatments: different jobs provide neighbouring routes. The Parkinson’s evidence here does not establish a VMAT2 defect, mitochondrial diagnosis or Parkinson’s mechanism in an individual with ADHD or another movement disorder. Each proposed connection still needs its own evidence.
Parkinson’s UK’s professional resource describes NHS testing pathways. In England and Wales, relevant specialists can request testing for diagnosed Parkinson’s before age 50, a first-degree relative diagnosed before 50, or specified complex features. Other UK nations have their own pathways. Check the current genomic directory and discuss counselling and the consequences of a result.
PD-TESTINGUseful questions are: what question would testing answer, which test fits it, and what would a positive, negative or uncertain result change? Research testing and clinical testing may have different purposes; ask how results and support will be provided.
Parkinson’s UK describes research aimed at better symptom treatments and approaches that could prevent, slow or reverse disease. These are research goals, not a statement that an available treatment has already achieved them.
PD-RESEARCHBefore treating a headline as actionable, look for the human study, comparison group, measured outcome, harms and stage of development. A cellular mechanism, animal result, biomarker change and meaningful clinical benefit are different levels of evidence. See How evidence is labelled.
The separate Saffron and Mucuna: what the evidence actually says page examines Mucuna evidence and its limitations. A plant source of levodopa is not automatically equivalent to a licensed, monitored medicine or a disease-modifying treatment.
Physiotherapy can support movement and function, occupational therapy can address daily tasks and home arrangements, and speech and language therapy can support communication and swallowing. A care plan should reflect current needs and be reviewed.
F12Ask what support can begin while other investigations continue. Bring the activities you cannot safely manage, the adjustments you need, and the most useful format for communication. Support for family and carers should be part of planning rather than left until they reach exhaustion.
Parkinson’s UK’s Get It On Time campaign addresses timely Parkinson’s medication in hospitals and care homes. Its resources are intended to help services give medication at the person’s prescribed times.
PD-ONTIMEParkinson’s medicines should not be stopped abruptly or subjected to unsupervised drug holidays. In hospital, administration should follow appropriate individual timing and specialist advice. If swallowing or medicine delivery becomes a problem, seek a prompt clinical plan.
F9A practical handover asks for:
The shared principle is safe continuity with an accountable plan. Parkinson’s-specific hazards and protocols should not be assumed identical to those of ADHD medicines. See When treatment stops and Transfers, shared care and Right to Choose for the wider handover questions.
Use Prepare for an appointment to turn the reading into the next decision you need. Ask a clinician or relevant organisation to correct any misleading statement; the source and review date should make a correction traceable.
This is a sourced educational guide, not an independent clinical review, diagnostic instrument or individual treatment plan. NICE indexed passages were checked but direct access to the recommendations page was blocked during this pass. Other linked institutional and charity pages were read directly. Research coverage is a starting framework, not an exhaustive systematic review or a claim that all current trials have been evaluated. Sources and pathways were checked on 7 October 2026; later changes should be verified at the originating source.